Cover Story Current Issue

Obesity affects a significant fraction of the world population, with some states or countries reporting overwhelming majority of the population as obese or overweight. Effective treatments were not readily available until the recent approval of glucagon-like peptide-1 (GLP-1) -based pharmacotherapeutics for weight loss. Since then, the use of GLP-1-based pharmacotherapies for the treatment of obesity has skyrocketed. In addition to or because of the effective weight loss, these medications affect many different organs in the body. Many of these effects, including the degree of weight loss achieved, show significant sex differences. Moreover, recent analysis of online patient communities identified a range of self-reported reproductive and endocrine side effects of GLP-1 based therapies including menstrual irregularities, reduced libido, and hot-flashes that have not been systematically captured in clinical trials. Some of these reports contrast with recent data indicating that in Polyendocrine Metabolic Ovarian Syndrome (PMOS; formerly Polycystic Ovary Syndrome) patients semaglutide-associated weight loss normalizes menstrual cycles in most patients, leaving this issue unresolved. While it has been established that sex and sex hormones affect the action of GLP-1 analogues, whether these medications affect the levels of sex hormones and reproductive organs is less well understood, especially in a chronic and clinically relevant drug application setting.

Full text

 

Current Issue

The diabetes gene Tcf7l2 organizes gene expression in the liver and regulates amino acid metabolism

Joanna Krawczyk, William O’Connor, Pedro Vendramini, Mareike Schell, ... Sudha B. Biddinger

The diabetes gene Tcf7l2 organizes gene expression in the liver and regulates amino acid metabolism

 

Objective

Though Tcf7l2 harbors the strongest genetic association with diabetes identified thus far, how it promotes metabolic disease remains unclear. Our aim was to dissect the contribution of hepatic TCF7L2.

Methods

Mice with liver-specific knockout of Tcf7l2 produced by targeted deletion of exon 1 were subjected to physiological characterization, single nucleus sequencing, and metabolite profiling. In parallel, a phenome-wide association study was performed in humans.

Results

We found that liver-specific deletion of Tcf7l2 had little effect on plasma glucose, but disrupted hepatic zonation. That is, many genes normally show gradients of expression across the liver lobule; in the absence of Tcf7l2, these gradients collapsed. One major consequence was the disorganization of glutamine metabolism, with a loss of the glutamine production program, ectopic expression of the glutamine consumption program, and a decrease in glutamine levels. In parallel, glutamine was found to be the most significantly decreased metabolite in the plasma of individuals harboring the rs7903146 variant in Tcf7l2.

Conclusions

Taken together, these data indicate that hepatic TCF7L2 has a secondary role in glycemic control, but a primary role in maintaining transcriptional architecture and glutamine homeostasis.

 

Articles in Press

The diabetes gene Tcf7l2 organizes gene expression in the liver and regulates amino acid metabolism

Joanna Krawczyk, William O’Connor, Pedro Vendramini, Mareike Schell, ... Sudha B. Biddinger

The diabetes gene Tcf7l2 organizes gene expression in the liver and regulates amino acid metabolism

 

Objective

Though Tcf7l2 harbors the strongest genetic association with diabetes identified thus far, how it promotes metabolic disease remains unclear. Our aim was to dissect the contribution of hepatic TCF7L2.

Methods

Mice with liver-specific knockout of Tcf7l2 produced by targeted deletion of exon 1 were subjected to physiological characterization, single nucleus sequencing, and metabolite profiling. In parallel, a phenome-wide association study was performed in humans.

Results

We found that liver-specific deletion of Tcf7l2 had little effect on plasma glucose, but disrupted hepatic zonation. That is, many genes normally show gradients of expression across the liver lobule; in the absence of Tcf7l2, these gradients collapsed. One major consequence was the disorganization of glutamine metabolism, with a loss of the glutamine production program, ectopic expression of the glutamine consumption program, and a decrease in glutamine levels. In parallel, glutamine was found to be the most significantly decreased metabolite in the plasma of individuals harboring the rs7903146 variant in Tcf7l2.

Conclusions

Taken together, these data indicate that hepatic TCF7L2 has a secondary role in glycemic control, but a primary role in maintaining transcriptional architecture and glutamine homeostasis.

 

2025 Impact Factor: 6.3

You are what you eat

Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.

Auf Werbeinhalte, die vor, während oder nach Videos von WEBSITE-URL eingeblendet werden, hat WEBSITE-URL keinen Einfluss. Wir übernehmen keine Gewähr für diese Inhalte. Weitere Informationen finden Sie hier.